NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Anuh Pharma ‘s Q3 2024-25 Latest News: Revenue Dropped by 7.31% YoY

February 7, 2025February 7, 2025| adminadmin| 0 Comments| 7:00 pm
[fetch_key]
Categories:

Share the post "Anuh Pharma ‘s Q3 2024-25 Latest News: Revenue Dropped by 7.31% YoY"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance.
🔹 Sales over the Year and quarter: The company’s sales declined by -7.31 % over the year, decrease in net sales/revenue by -3.88 %.
🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -74.35 %, Marginal decrease of -72.41% in other income during this quarter.
🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Anuh Pharma Limited. Profit dropped by -45.88 % Year to Year, Anuh Pharma Limited’s profitability dropped by -31.24 % Quarter to Quarter.
🔹 EPS over the Year and quarter: EPS declined by -45.93 % Year to Year. EPS decreased by -31.33 % in previous quarter. Analysis needed for shareholder value.

This report meticulously dissects the performance of Anuh Pharma Limited, offering a panoramic view of its operational success and challenges. It delves into a variety of financial metrics, such as revenue growth, profit margins, and shareholder returns, juxtaposed against the backdrop of broader economic conditions and sector-specific trends. The analysis further explores the investor community’s perception and expectations, which influence the stock’s volatility and potential returns. By providing a forecast based on quantitative analyses and market sentiment, the report aims to outline the potential risks and rewards, guiding investors toward making strategic, data-driven investment choices.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 172.101 Cr Rs. 165.954 Cr Rs. 159.513 Cr -3.88 % -7.31 %
Expenses Rs. 148.11 Cr Rs. 149.08 Cr Rs. 144.72 Cr -2.92 % -2.29 %
Operating Profit Rs. 23.99 Cr Rs. 16.87 Cr Rs. 14.79 Cr -12.33 % -38.35 %
OPM % 13.94 % 10.17 % 9.27 % -0.9 % -4.67 %
Other Income Rs. 3.657 Cr Rs. 3.4 Cr Rs. 0.938 Cr -72.41 % -74.35 %
Interest Rs. 0.14 Cr Rs. 0.16 Cr Rs. 0.28 Cr + 75 % + 100 %
Depreciation Rs. 2.2 Cr Rs. 1.92 Cr Rs. 2.18 Cr + 13.54 % -0.91 %
Profit before tax Rs. 25.31 Cr Rs. 18.19 Cr Rs. 13.27 Cr -27.05 % -47.57 %
Tax % 24.47 % 17.32 % 22.03 % + 4.71 % -2.44 %
Net Profit Rs. 19.11 Cr Rs. 15.04 Cr Rs. 10.34 Cr -31.25 % -45.89 %
EPS in Rs Rs. 3.81 Rs. 3 Rs. 2.06 -31.33 % -45.93 %


Today, we’re looking at Anuh Pharma Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -7.31 %. However, it did see a marginal slip of -3.88 % from the previous quarter. Expenses decreased slightly by -2.92 % quarter-on-quarter, aligning with the annual decline of -2.29 %. Operating profit, while down -38.35 % compared to last year, faced a quarter-on-quarter dip of -12.33 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -4.67 %, but a shrinkage of -0.9 % sequentially. Other income fell by -72.41 % compared to the last quarter, despite an annual decline of -74.35 %. Interest expenses surged remarkably by 75 % from the previous quarter, yet the year-over-year increase remains at a moderate 100 %. Depreciation costs climbed by 13.54 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -0.91 %. Profit before tax declined annually by -47.57 % but saw a reduction from the preceding quarter by -27.05 %.
Tax expenses as a percentage of profits decreased slightly by -2.44 % compared to last year, with a more notable quarter-on-quarter increase of 4.71 %. Net profit fell by -45.89 % year-on-year but witnessed a -31.25 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -45.93 % but a quarterly fall of -31.33 %. In summary, Anuh Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 172.101 Cr Rs. 165.954 Cr Rs. 159.513 Cr -3.88 % -7.31 %
Expenses Rs. 148.11 Cr Rs. 149.08 Cr Rs. 144.72 Cr -2.92 % -2.29 %
Operating Profit Rs. 23.99 Cr Rs. 16.87 Cr Rs. 14.79 Cr -12.33 % -38.35 %
Net Profit Rs. 19.11 Cr Rs. 15.04 Cr Rs. 10.34 Cr -31.25 % -45.89 %
EPS in Rs Rs. 3.81 Rs. 3 Rs. 2.06 -31.33 % -45.93 %


In reviewing Anuh Pharma Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -7.31 % year-on-year, although there was a slight dip of -3.88 % from the previous quarter. Expenses decreased by -2.29 % compared to the previous year, with a decrease of -2.92 % quarter-on-quarter. Operating Profit dropped by -38.35 % annually, and saw a -12.33 % decrease from the last quarter.
Net Profit showed yearly decrease of -45.89 %, and experienced a -31.25 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -45.93 % annually, however dipped by -31.33 % compared to the last quarter. In essence, while Anuh Pharma Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

Join our telegram for more updates

Stay Updated with Our YouTube Videos

Related Post